Please select the outcome measures that correspond to the clinical trial below.
Title: Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Brief Summary: The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are not being treated with curative intent. The palliative care services provided to patients randomized to the intervention will be provided by board-certified physicians and/or advanced practice nurses and will focus on the following areas: (1) developing and maintaining the therapeutic relationship with the patients and family caregivers; (2) assessing and treating patient symptoms; (3) providing support and reinforcement of coping with advanced cancer in patients and family caregivers; (4) assessing and enhancing prognostic awareness and illness understanding in patients and family caregivers; (5) assisting with treatment decision-making; and (6) end-of-life care planning.


Options:
A: Change in Quality of Life (QOL) From Baseline to Week 12 Per the Functional Assessment of Cancer Therapy-General (FACT-G) (Up to 12 weeks)
B: depressive symptoms (3 to 28 days)
C: HADS Anxiety (2-4 weeks prior to drug administration); HADS Anxiety (1 day prior to drug administration 1); HADS Anxiety (1 day post drug administration 1); HADS Anxiety (6 weeks post drug administration 1); HADS Anxiety (1 day prior to drug administration 2); HADS Anxiety (6 weeks post drug administration 2); HADS Anxiety (26 weeks post drug administration 2); State-Trait Anxiety Inventory (STAI) State (2-4 weeks prior to drug administration/ Baseline); STAI State (1 day prior to drug administration 1); STAI State (1 day post drug administration 1); HADS Depression (2-4 weeks prior to drug administration/ Baseline); STAI State (6 weeks post drug administration 1); STAI State (1 day prior to drug administration 2); STAI State (1 day post drug administration 2); STAI State (6 weeks post drug administration 2); STAI State (26 weeks post drug administration 2); STAI Trait (2-4 weeks prior to drug administration/ Baseline); STAI Trait (1 day prior to drug administration 1); STAI Trait (1 day post drug administration 1); STAI Trait (6 weeks post drug administration 1); STAI Trait (1 day prior to drug administration 2); STAI Trait (1 day post drug administration 2); STAI Trait (6 weeks prior to drug administration 2); STAI Trait (6 weeks post drug administration 2); HADS Depression (1 day prior to drug administration 1); HADS Depression (1 day post drug administration 1); HADS Depression (6 weeks post drug administration 1); HADS Anxiety (1 day post drug administration 2); HADS Depression (1 day post drug administration 2); HADS Depression (6 weeks post drug administration 2); HADS Depression (26 weeks post drug administration 2)
D: Cycle 1 Sensory Neuropathy Score (Items 31-36, 39, 40 and 48) of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 (Up to 2 weeks)

Answer: A